<DOC>
	<DOCNO>NCT00397761</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , capecitabine paclitaxel ( albumin-stablized nanoparticle formulation , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) surgery may make tumor small reduce amount normal tissue need remove . PURPOSE : This phase II/III trial study well give capecitabine together paclitaxel ( albumin-stabilized nanoparticle formulation ) work treat woman undergo surgery stage II stage III breast cancer .</brief_summary>
	<brief_title>Capecitabine Paclitaxel ( Albumin-Stabilized Nanoparticle Formulation ) Treating Women Undergoing Surgery Stage II Stage III Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine rate pathological complete response ( i.e. , tumor completely go ) woman previously untreated , unresected , stage II-IIIB breast cancer treat neoadjuvant therapy comprise capecitabine paclitaxel ( albumin-stabilized nanoparticle formulation ) ( Abraxane^速 ) . Secondary - Evaluate safety regimen patient . - Determine overall clinical response rate patient treat regimen . OUTLINE : Patients receive 4 course capecitabine paclitaxel ( nanoparticle albumin-stabilized formulation ) ( Abraxane^速 ) absence disease progression . Patients undergo definitive surgical resection tumor study . PROJECTED ACCRUAL : A total 33 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm infiltrate carcinoma breast inflammatory breast cancer Stage IIIIIB disease ( T14 , N12 , M0 ) Previously untreated disease Previously unresected disease Highrisk disease resectable lumpectomy alone Any HER2/neu status ( positive , negative , unknown ) allow Hormone receptor status : Any estrogen/progesterone status ( positive , negative , unknown ) allow PATIENT CHARACTERISTICS : Female Menopausal status specify ECOG performance status 02 Life expectancy &gt; 3 month Absolute neutrophil count &gt; 1,500/mm続 Platelet count &gt; 100,000/mm続 Hemoglobin &gt; 9.0 g/dL Creatinine &lt; 1.5 mg/dL Bilirubin &lt; 1.5 time upper limit normal ( ULN ) ALT AST &lt; 2.5 time ULN ( 5 time ULN due Gilbert 's disease ) Alkaline phosphatase &lt; 2.5 time ULN ( 5 time ULN due Gilbert 's disease ) PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>inflammatory breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
</DOC>